Innovation Culture
Innovation driving creation of differentiated and sustainable business models
Through our innovation-led approach, the Company has created differentiated business models that have been tested even in the most difficult business environments and have consistently delivered stronger performance. In Financial Services, the innovative differentiation in our business model primarily includes:
End-to-end real estate financing platform to partner with developers throughout the project life-cycle
100% secured lending
B2B2C Housing Finance business, with focus on building a technology-driven model
Strong relationships with tier-1 developers
Ability to cross-collateralise and innovatively structure deals
Ability to take over, complete and sell the project, if needed
Created the 2nd largest Real estate developer financing platform in India with a loan book size of `56,624 Crores
Integrated service-led platform creating significant values for customers
The differentiation in our Pharma business model primarily includes:
Built niche capabilities across complex products in injectable anesthesia, inhalation anesthesia, intrathecal spasticity and pain management
Integrated model of contract manufacturing services spanning across the entire drug life-cycle
Built strong capabilities in niche Highly Potency APIs and Antibody Drug Conjugates
Considered as a preferred integrated partner in the area of cancer
Focusing on e-commerce to expand India Consumer Products business
Over 90% of revenues derived from niche businesses of complex generics and CDMO, as compared with less than 5% for most large Indian pharma companies
Note: Pharma peer set includes (not necessarily in the same order) Aurobindo Pharma, Cipla, Dr. Reddy’s Lab, Lupin and Sun Pharma
PEL’s Strong presence in Specialty and CDMO
